Omnicell Stock Forecast, Price & News

+3.82 (+2.56 %)
(As of 08/5/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume382,297 shs
Average Volume325,577 shs
Market Capitalization$6.61 billion
P/E Ratio117.70
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

Omnicell logo

About Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.39 out of 5 stars

Medical Sector

1056th out of 1,311 stocks

Electronic Computers Industry

8th out of 11 stocks

Analyst Opinion: 1.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

Is Omnicell a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Omnicell stock.
View analyst ratings for Omnicell
or view top-rated stocks.

What stocks does MarketBeat like better than Omnicell?

Wall Street analysts have given Omnicell a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Omnicell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for Omnicell

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Thursday, July, 29th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.42. Omnicell had a net margin of 6.05% and a trailing twelve-month return on equity of 11.06%.
View Omnicell's earnings history

How has Omnicell's stock been impacted by COVID-19 (Coronavirus)?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OMCL stock has increased by 97.7% and is now trading at $153.01.
View which stocks have been most impacted by COVID-19

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of $3.650-$3.750 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.590. The company issued revenue guidance of $1.10 billion-$1.12 billion, compared to the consensus revenue estimate of $1.10 billion.

What price target have analysts set for OMCL?

8 brokerages have issued 12 month price targets for Omnicell's stock. Their forecasts range from $84.00 to $188.00. On average, they expect Omnicell's stock price to reach $138.07 in the next twelve months. This suggests that the stock has a possible downside of 9.8%.
View analysts' price targets for Omnicell
or view top-rated stocks among Wall Street analysts.

Who are Omnicell's key executives?

Omnicell's management team includes the following people:
  • Randall A. Lipps, Chairman, President & Chief Executive Officer
  • Bill Wingfield, Vice President-North America Service & Operations
  • Peter J. Kuipers, Chief Financial Officer & Executive Vice President
  • Giri Chodavarapu, Chief Information Officer
  • Scott Seidelmann, Chief Commercial Officer & Executive VP

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell CEO Randall A. Lipps on Randall A. Lipps has an approval rating of 68% among Omnicell's employees.

Who are some of Omnicell's key competitors?

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.35%), Victory Capital Management Inc. (1.03%), American Century Companies Inc. (0.88%), Paradigm Capital Management Inc. NY (0.74%), Scout Investments Inc. (0.57%) and Fisher Asset Management LLC (0.56%). Company insiders that own Omnicell stock include Christine Marie Mellon, Dan S Johnston, Joanne B Bauer, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell

Which major investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Ziegler Capital Management LLC, Los Angeles Capital Management LLC, Avory & Company LLC, Scout Investments Inc., American Century Companies Inc., Rice Hall James & Associates LLC, Peregrine Capital Management LLC, and Victory Capital Management Inc.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Peter J Kuipers, Randall A Lipps, and Robin Gene Seim.
View insider buying and selling activity for Omnicell
or view top insider-selling stocks.

Which major investors are buying Omnicell stock?

OMCL stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Impax Asset Management Group plc, Arkadios Wealth Advisors, Envestnet Asset Management Inc., Congress Asset Management Co. MA, Fisher Asset Management LLC, Conestoga Capital Advisors LLC, and Advisor Group Holdings Inc..
View insider buying and selling activity for Omnicell
or or view top insider-buying stocks.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $153.01.

How much money does Omnicell make?

Omnicell has a market capitalization of $6.61 billion and generates $892.21 million in revenue each year. The company earns $32.19 million in net income (profit) each year or $1.74 on an earnings per share basis.

How many employees does Omnicell have?

Omnicell employs 2,860 workers across the globe.

What is Omnicell's official website?

The official website for Omnicell is

Where are Omnicell's headquarters?

Omnicell is headquartered at 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at (650) 251-6100 or via email at [email protected]

This page was last updated on 8/5/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.